JB Capital LLC Increases Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

JB Capital LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 7.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 33,729 shares of the medical device company’s stock after purchasing an additional 2,259 shares during the period. JB Capital LLC owned about 0.05% of Tandem Diabetes Care worth $1,430,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of TNDM. Vanguard Group Inc. boosted its stake in shares of Tandem Diabetes Care by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after purchasing an additional 30,664 shares in the last quarter. Fred Alger Management LLC lifted its stake in shares of Tandem Diabetes Care by 45.2% in the 2nd quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock valued at $87,595,000 after acquiring an additional 677,036 shares during the last quarter. Bellevue Group AG increased its stake in Tandem Diabetes Care by 2.0% in the 1st quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock worth $71,949,000 after purchasing an additional 39,571 shares during the period. Stephens Investment Management Group LLC grew its holdings in Tandem Diabetes Care by 12.2% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,274,482 shares of the medical device company’s stock worth $54,051,000 after acquiring an additional 138,263 shares during the last quarter. Finally, Chicago Capital LLC boosted its stake in Tandem Diabetes Care by 22.2% during the third quarter. Chicago Capital LLC now owns 1,003,147 shares of the medical device company’s stock worth $42,543,000 after acquiring an additional 182,085 shares in the last quarter.

Tandem Diabetes Care Price Performance

Shares of TNDM stock traded down $1.09 during mid-day trading on Thursday, hitting $33.15. 1,262,934 shares of the stock were exchanged, compared to its average volume of 1,585,113. The company has a market cap of $2.17 billion, a PE ratio of -16.38 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 52-week low of $13.82 and a 52-week high of $53.69. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average of $39.21 and a 200 day moving average of $41.88.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TNDM shares. Wells Fargo & Company boosted their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $55.00 price objective (up from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Morgan Stanley reissued an “equal weight” rating and set a $45.00 price target on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Royal Bank of Canada began coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 target price for the company. Finally, UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.31.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.